HercepTest™ is a semi-quantitative immunohistochemical assay for determination of HER2 protein (c-erbB-2 oncoprotein) overexpression in breast cancer tissues routinely processed for histological evaluation and formalin-fixed, paraffin-embedded cancer tissue from patients with adenocarcinoma of the stomach, including the gastro-esophageal junction. HercepTest™ with the indication adenocarcinoma of the stomach, including the gastroesophageal junction, is not available on selected markets. HercepTest™ specifically demonstrates overexpression of HER2 protein.

HercepTest™ is indicated as an aid in the assessment of patients for whom Herceptin™ (trastuzumab) treatment is being considered.

HercepTest™ and Herceptin™ are trademarks of Genentech, Inc. subject to licenses held by Dako Denmark A/S and F. Hoffmann-La Roche Ltd.